FDA Announces Enforcement Priorities to Restrict Compounded Semaglutide Products

The FDA announced definitive new enforcement priorities to restrict the use of GLP-1 ingredients in unapproved compounded products, a move the agency said is intended to protect consumers from escalating public health risks. The agency affirmed it will use all available enforcement tools, including seizure and injunction, to address violations involving compounded GLP-1 drugs.

On February 6, 2026, the FDA Commissioner stated the agency's intent to "take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed." The announcement represented a significant escalation in the FDA's approach to compounded versions of popular GLP-1 drugs such as semaglutide.

The enforcement action followed an August 2025 citizens' petition filed on behalf of Adventa Pharma urging the FDA to address the risks associated with compounded GLP-1 products. The petition sought clarification on guidance regarding the manufacture, risk assessment procedures, product misbranding, and study mandates for compounded semaglutide.

The petition argued that the large-scale production and distribution of compounded semaglutide products has risen beyond the traditional practice of customized pharmacy compounding and that these products are a danger to public health. Among the specific concerns highlighted were the lack of immunogenicity risk assessments, the use of unapproved salt forms, and misleading "mass-marketing" practices by compounders.

The FDA's decision to act on these concerns has significant implications for the pharmaceutical and health care industries, particularly as compounded semaglutide products have proliferated in the market as lower-cost alternatives to FDA-approved versions of the weight loss and diabetes medication.